Diabetes: how to manage cardiovascular risk in secondary prevention patients
Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure-lowering therapies, lipid-lowering therapies and h...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BioExcel Publishing Ltd
2022-06-01
|
| Series: | Drugs in Context |
| Subjects: | |
| Online Access: | https://www.drugsincontext.com/diabetes-how-to-manage-cardiovascular-risk-in-secondary-prevention-patients |
| _version_ | 1818204233985425408 |
|---|---|
| author | Sarah L Anderson Joel C Marrs |
| author_facet | Sarah L Anderson Joel C Marrs |
| author_sort | Sarah L Anderson |
| collection | DOAJ |
| description | Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure-lowering therapies, lipid-lowering therapies and healthy lifestyle modifications. In the past decade, multiple antihyperglycaemic agents have emerged as CV risk-lowering therapies in this population as well. This article provides a narrative review on the current non-glycaemic and glycaemic treatment options for CV risk reduction in patients with T2D and ASCVD. The FDA requirement that all new antihyperglycaemic agents undergo cardiovascular outcomes trials has demonstrated increasing evidence to support the role of glucagon-like peptide 1 (GLP1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors as first-line agents for both glycaemic control and CV risk reduction in this population. |
| first_indexed | 2024-12-12T03:37:59Z |
| format | Article |
| id | doaj.art-7aaf37606bde4ec2a75b64c836f891a8 |
| institution | Directory Open Access Journal |
| issn | 1740-4398 |
| language | English |
| last_indexed | 2024-12-12T03:37:59Z |
| publishDate | 2022-06-01 |
| publisher | BioExcel Publishing Ltd |
| record_format | Article |
| series | Drugs in Context |
| spelling | doaj.art-7aaf37606bde4ec2a75b64c836f891a82022-12-22T00:39:45ZengBioExcel Publishing LtdDrugs in Context1740-43982022-06-011111210.7573/dic.2021-10-1Diabetes: how to manage cardiovascular risk in secondary prevention patientsSarah L AndersonJoel C MarrsAtherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure-lowering therapies, lipid-lowering therapies and healthy lifestyle modifications. In the past decade, multiple antihyperglycaemic agents have emerged as CV risk-lowering therapies in this population as well. This article provides a narrative review on the current non-glycaemic and glycaemic treatment options for CV risk reduction in patients with T2D and ASCVD. The FDA requirement that all new antihyperglycaemic agents undergo cardiovascular outcomes trials has demonstrated increasing evidence to support the role of glucagon-like peptide 1 (GLP1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors as first-line agents for both glycaemic control and CV risk reduction in this population.https://www.drugsincontext.com/diabetes-how-to-manage-cardiovascular-risk-in-secondary-prevention-patientsatherosclerotic cardiovascular diseasecardiovascular diseasediabetesglp1 receptor agonistssglt2 inhibitorstype 2 diabetes |
| spellingShingle | Sarah L Anderson Joel C Marrs Diabetes: how to manage cardiovascular risk in secondary prevention patients Drugs in Context atherosclerotic cardiovascular disease cardiovascular disease diabetes glp1 receptor agonists sglt2 inhibitors type 2 diabetes |
| title | Diabetes: how to manage cardiovascular risk in secondary prevention patients |
| title_full | Diabetes: how to manage cardiovascular risk in secondary prevention patients |
| title_fullStr | Diabetes: how to manage cardiovascular risk in secondary prevention patients |
| title_full_unstemmed | Diabetes: how to manage cardiovascular risk in secondary prevention patients |
| title_short | Diabetes: how to manage cardiovascular risk in secondary prevention patients |
| title_sort | diabetes how to manage cardiovascular risk in secondary prevention patients |
| topic | atherosclerotic cardiovascular disease cardiovascular disease diabetes glp1 receptor agonists sglt2 inhibitors type 2 diabetes |
| url | https://www.drugsincontext.com/diabetes-how-to-manage-cardiovascular-risk-in-secondary-prevention-patients |
| work_keys_str_mv | AT sarahlanderson diabeteshowtomanagecardiovascularriskinsecondarypreventionpatients AT joelcmarrs diabeteshowtomanagecardiovascularriskinsecondarypreventionpatients |